News Release

Rohto Pharmaceutical launches AI project utilizing Microsoft's innovation hub, "Microsoft AI Co-Innovation Lab Kobe"

Rohto Pharmaceutical has released its "Children's Eye Health White Paper 2024." One in three elementary school children has uncorrected visual acuity of less than 1.0.

Rohto Pharmaceutical's original complete AOF culture medium "R:STEM" receives the first FIRM mark certification in Japan.

We are pleased to announce the launch of "TokoChalle 2024 Sleep+", a company-wide initiative to improve health and productivity management progress, exercise habits, and sleep, starting in Spring 2024.

Utilizing data science, thrombospondin-1 (THBS1) was identified as an effective factor against skin aging

ROHTO V5 Wan" is now available! It supports the eye and overall health of dogs.

Notification regarding provision of cell preparation "ADR001" in investigator-initiated clinical trial

Notice of Contract Signing for the Development of a Medical Device for the Repair of Meniscus Injuries

Lab & office opened at "Nakanoshima Qross (Future Medical International Center)"

Rohto establishes the "Rohto Children's Dream Fund" to address social issues surrounding children.